Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $13.6M fell 52.8% year over year, behind the -33.8% change in trailing-twelve-month research & development. Sequentially, it fell 24.4% from the prior quarter. Over 3 fiscal years it compounded at +0.5% a year.

Context

  • Research & development amounted to 776.8% of revenue in FY2025, down 908.9 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -52.8% toward the trailing-twelve-month pace of -33.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$13.6M-24.4% QoQ
Last fiscal yearDec 2025
$94.3M-20.1% YoY
LTMMar 2026
$79.09M-33.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-52.8%——
1 year-20.1%——
3-year CAGR+0.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
94.3M USD
Year-over-year change
-20.1%
4-year CAGR
+2.1%

Research & Development vs competitors

How PRLD compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -33.8% is the lowest of 11, against a peer median of +6.7%.
  • Research & development amounts to 473.0% of revenue for PRLD, versus a peer median of 696.9%.
PRLD Competitors
Research & Development for PRLD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$10.68B USD+22061.7%+5.1%—
CRBUCaribou Biosciences, Inc.LTM Mar 2026$94.52M USD-28.3%+10.0%843.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M USD-20.8%-13.4%131.9%
IVAInventiva S.A.FY2025€83.61M EUR-8.0%+11.4%1865.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$82.1M USD-9.4%-6.8%290.9%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$79.09M USD-33.8%+0.5%473.0%
PYXSPyxis Oncology, Inc.LTM Mar 2026$76.25M USD+21.5%-5.1%550.2%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$62.37M USD-24.6%-10.1%27721.8%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$60.48M USD+28.2%+38.4%184.8%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$55.01M USD+74.4%+17.0%93235.6%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$27.18M USD+72.6%+29.4%—
Peer median (excluding PRLD) —+6.7%+7.5%696.9%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0007M12.14M
Cost of Revenue00001.71M
Gross Profit0007M10.43M
Gross Margin———100.0%85.9%
Research & Development86.78M92.89M103.39M118M94.3M
Selling, General & Admin26.96M30.65M28.88M28.72M22.41M
Operating Expenses113.74M123.54M132.28M146.71M115M
Depreciation & Amortization915K1.32M1.17M1.77M1.71M
EBITDA(110.78M)(114.11M)(120.66M)(125.4M)(97.79M)
EBITDA Margin———-1791.4%-805.5%
Operating Income(113.74M)(123.54M)(132.28M)(139.71M)(104.57M)
Operating Margin———-1995.9%-861.3%
Interest Income00000
Interest Expense00000
Other Income / Expenses2.04M8.1M10.44M12.54M5.07M
Income Before Tax(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Pre-Tax Margin———-1816.8%-819.6%
Income Tax Expense00000
Net Income(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Net Margin———-1816.8%-819.6%
EPS (Basic)(2.33)(2.27)(2.02)(1.68)(1.29)
EPS (Diluted)(2.33)(2.27)(2.02)(1.68)(1.29)
Weighted Avg Shares47.6M47.37M60.36M75.81M76.96M
Weighted Avg Shares (Diluted)47.6M47.37M60.36M75.81M76.96M

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.